Amphiphilic Cyclodextrin?Based Nanoparticulate Vaccines Can Trigger T?Cell Immune Responses

Particulate antigen-delivery systems are instrumental for therapeutic vaccination, aiming at improving the safety and efficacy of treatments by targeting specialized antigen-presenting cells (APCs). However, induction potent adaptive immune responses, especially cellular immunity, remains a major challenge. Herein, novel nanoparticulate system based on amphiphilic cyclodextrins (CDs) is developed as platform cancer vaccination. Supramolecular nanosized CD structures formed in aqueous media loaded with peptide antigens. The nanoparticle's adjuvant capacity tested cell experiments murine bone marrow-derived dendritic (BMDCs) or macrophages T cells. Peptide-loaded nanoparticles cause upregulation costimulatory molecules BMDCs facilitate activation proliferation antigen-specific T-lymphocytes vitro. Correct processing histocompatibility complex (MHC) class-I antigen presentation demonstrated using capped version ovalbumin-derived SIINFEKL (c-SFL). After immunization mice peptide-loaded nanoparticles, frequencies cytokine-producing CD8+ increased. This work sheds light immune-stimulating properties reveals their considerable potential carriers vaccines.